Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030868 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT07030868: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT07030868 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07030868, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months.
Primary Outcome
Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.
Interventions
- DRUG Placebo
- DRUG LY6249492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 2 |
Why NCT07030868 stopped before completion
NCT07030868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07030868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07030868 about?
NCT07030868 is a clinical study titled "A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes". The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 mont...
What is the current status of trial NCT07030868?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2025-06-19. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT07030868?
The interventions under investigation include: Placebo (DRUG), LY6249492 (DRUG).
Who is sponsoring clinical trial NCT07030868?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07030868's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI